Johnson & Johnson reported a 1.7 percent rise in fourth-quarter sales, due to a strong demand for its newer products.
The diversified healthcare company’s sales rose to $18.11 billion in the fourth quarter from $17.81 billion a year earlier.
Net earnings rose to $3.81 billion, or $1.38 per share, from $3.22 billion, or $1.15 per share.
The band-aid maker also said on Tuesday that it was looking to divest its diabetes care division.
By Natalie Grover
Source: Reuters
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.